Is this front‑of‑knee pain actually patellofemoral arthritis?

Trouble going downstairs, kneeling, or getting up from a low chair often points towards the joint between the kneecap and the thigh bone. Patellofemoral arthritis involves wear of the cartilage on the underside of the patella and the groove (trochlea) it runs in, and it often presents as pain at the front of the knee with activities such as squatting and stair use. To avoid a tick-box symptom list, this section uses a simple “pattern match”: front-of-knee load sensitivity tends to fit patellofemoral involvement better than pain that is mainly deep in the joint or at one side.

Pain that sits on the inner or outer “joint line”, swelling after a specific twist, or true locking can sometimes suggest more tibiofemoral or meniscal involvement; overlap is common, and mixed-compartment arthritis is not unusual.

In practice, the working diagnosis is usually built from the history and examination first, with X‑ray (and sometimes MRI) used to clarify which compartment looks most affected rather than to chase every small change. Recognising a patellofemoral pattern early helps tailor rehabilitation and frames how much evidence exists for particular injections in this compartment.

What should I do before thinking about injections?

A practical checkpoint before injections is making sure the basics have had a real run—measured in weeks to months, not a few days of generic exercises.

Load management (not full rest)

Activity tweaks that reduce peak kneecap load—shorter stairs exposure, fewer deep squats, pacing hills—often help symptoms settle enough to train. Where relevant, weight optimisation can reduce day-to-day joint load.

Strength and control

High-quality physiotherapy usually means supervised progression and adjustments over time, not just being handed a sheet. Programmes commonly target quadriceps strength plus hip and glute control, alongside mobility and movement retraining.

Early rehab after injury or surgery

In post‑traumatic patterns, early work on swelling control, range of motion, and restoring muscular control after a ligament/meniscus injury can matter for long‑term joint overload.

Basics for pain

Simple options such as paracetamol and topical NSAIDs (where suitable) may help make rehab tolerable.

Where do injections fit for patellofemoral arthritis after physio?

Evidence for injections that specifically target the patellofemoral joint is relatively thin compared with the broader knee osteoarthritis literature, so decisions for “front-of-knee arthritis” often rely on a smaller set of compartment-specific data plus clinical judgement about the pain pattern.

When injections are considered after a properly trialled strengthening and load-management programme, most of the best-available evidence still comes from mixed “general knee OA” populations rather than patellofemoral-only cohorts. In larger overviews of knee OA injection research, the overall evidence base spans many decades and hundreds of studies, but relatively few trials are designed to demonstrate true disease modification (i.e., stopping progression), so injections are usually framed as tools for symptoms and function rather than a way to “reset” the joint.

In practice, steroid injections are often used for short-lived symptom flares or when it is helpful to test how much pain is coming from inflammation inside the joint, with the aim of creating a more manageable window for ongoing rehabilitation rather than replacing it.

How does post‑traumatic knee arthritis change the injection conversation?

An ACL rupture at 28, a meniscus tear in the 30s, or a patellar fracture can leave a knee that feels “fine” for years and then develops recurring swelling and a deep ache with sport or long days. That pattern is still osteoarthritis—just arising after a specific injury rather than age alone—and some reviews estimate around 25–50% of people with major ligament or meniscal injuries go on to develop osteoarthritis over time.

What makes post‑traumatic OA feel different is the biology early on: reviews highlight inflammation and bleeding into the joint (haemarthrosis) after injury as potential drivers of later cartilage damage, which is why anti‑inflammatory and biologic approaches attract interest. However, even across large bodies of injection studies in knee OA, relatively few trials are designed to show genuine disease modification, so injections are still mainly framed as symptom and function tools rather than a way to “stop” PTOA.

In practical terms, the long time horizon (often decades) shifts the emphasis towards repeatability and durability, not just speed of relief. Most evidence still comes from mixed “general knee OA” cohorts, but it can guide expectations: corticosteroid tends to provide more short-term relief, while hyaluronic acid tends to show more benefit at later follow-up (with overall effects usually described as moderate).

How do cortisone, hyaluronic acid, PRP and hydrogel compare as single injections?

Single-injection choices tend to differ less by whether they can help and more by how quickly they tend to kick in, how long benefits may last, and how solid the evidence is.

Speed of relief: fastest vs slower-build options

Across comparative trials, corticosteroid (cortisone) injections tend to win on early pain relief (often measured over the first few weeks), while hyaluronic acid (HA/viscosupplementation) more often looks better later on (follow-ups out to roughly 6 months)—with the overall size of benefit described as moderate and most consistent in mild–moderate OA. That “fast vs slow-build” split is a useful way of thinking about the two options even when the average end result looks similar.

Durability and magnitude: where PRP sits

For PRP, narrative syntheses of higher-quality clinical evidence commonly report that PRP—particularly leukocyte-poor preparations—tends to produce greater improvements in pain and function than hyaluronic acid or corticosteroid injections in mild to moderate knee osteoarthritis, while also noting protocol variability and that placebo-controlled trials do not show consistent long-term superiority across all studies. A European consensus statement (ESSKA-ORBIT) concluded there is sufficient preclinical and clinical evidence to support PRP use for knee osteoarthritis, particularly in mild–moderate disease, while also highlighting that many protocol details rely on lower-level evidence or expert opinion.

Risks, repeat injections, and why guidelines diverge

Large real-world data on HA (including 694,404 injections) suggest severe acute localised reactions needing medical attention within 3 days are very rare (≤0.03%), and umbrella-review level evidence generally describes mostly mild-to-moderate adverse events with substantial heterogeneity in efficacy findings—one reason guideline recommendations on HA diverge.

• Three practical takeaways (speed vs durability vs certainty):
• Steroid and HA often trade faster onset (steroid) against longer medium-term control (HA), with modest average effects.
• PRP tends to show larger average improvements than HA or steroid in many syntheses, but protocols vary and post-traumatic-specific data remain sparse.
• For all injectables, the strongest evidence base is still for symptom and function change rather than proven disease modification.

How should I decide what to try next?

Decision-making works best when the next step is chosen to match the main goal and time horizon—pain control for day-to-day walking over the next 4–12 weeks, getting through a specific event in 3 months, or buying longer-term headroom while rehab continues. To move away from a “which injection is best?” Q&A feel, this section is framed as a short checklist for a clinic conversation rather than another set of self-posed questions.

A practical sequence to discuss

• Confirm the pattern (patellofemoral-dominant vs more general knee OA) and revisit what has already been tried in physiotherapy over weeks to months.
• Choose the role of an injection: for a short flare window, an intra-articular steroid is often discussed; for a more “slow-build” option with generally good tolerability (but mixed guideline positions), hyaluronic acid may be considered; for those prioritising symptom change (often self-funded), PRP is often positioned as a higher-efficacy option in mild–moderate OA, while noting protocol variability and that not all trials show consistent long-term superiority.

Questions that make the decision concrete

• What benefit is realistic in this knee over 1 month and 6–12 months?
• How will response be measured (pain score, WOMAC/function, stairs, swelling frequency)?
• If it helps, how often can it be repeated—and what are the key risks with repeat use?

If function remains poor despite well-executed rehab plus one or more injection attempts, it becomes reasonable to discuss surgical pathways (for example cartilage procedures, osteotomy, or knee replacement) as the next tool—aiming to restore quality of life rather than framing it as “failure”.

1. [1] The use of injectable orthobiologics for knee osteoarthritis: A European ESSKA-ORBIT consensus. Part 1-Blood-derived products (platelet-rich plasma). (2024). https://doi.org/10.1002/ksa.12077 https://doi.org/10.1002/ksa.12077